Literature DB >> 21221077

Pfizer reaches out to academia--again.

Mark Ratner.   

Abstract

Mesh：

Year:  2011        PMID： 21221077     DOI： 10.1038/nbt0111-3

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Profile: Corey Goodman.

Authors:  Jim Kling
Journal:  Nat Biotechnol       Date:  2009-04       Impact factor: 54.908
  1 in total
  12 in total

1.  Industry continues dabbling with open innovation models.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2011-12-08       Impact factor: 54.908

2.  Big pharma upheavals cast shadow across biotech sector.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2012-02-08       Impact factor: 54.908

3.  Medicinal chemistry for 2020.

Authors:  Seetharama D Satyanarayanajois; Ronald A Hill
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

4.  Scripps boosts research coffers by selling reagents to Sigma-Aldrich.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2013-10       Impact factor: 54.908

5.  Biotechs follow big pharma lead back into academia.

Authors:  Jim Kling
Journal:  Nat Biotechnol       Date:  2011-07-11       Impact factor: 54.908

6.  An NIH National Center for Advancing Translational Sciences: is a focus on drug discovery the best option?

Authors:  Bruce H Littman
Journal:  Nat Rev Drug Discov       Date:  2011-05-20       Impact factor: 84.694

7.  Reinventing tech transfer.

Authors:  Brady Huggett
Journal:  Nat Biotechnol       Date:  2014-12       Impact factor: 54.908

8.  Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS).

Authors:  Harry Shamoon; David Center; Pamela Davis; Mendel Tuchman; Henry Ginsberg; Robert Califf; David Stephens; Thomas Mellman; Joseph Verbalis; Lee Nadler; Anantha Shekhar; Daniel Ford; Robert Rizza; Reza Shaker; Kathleen Brady; Barbara Murphy; Bruce Cronstein; Judith Hochman; Philip Greenland; Eric Orwoll; Lawrence Sinoway; Harry Greenberg; Rebecca Jackson; Barry Coller; Eric Topol; Lisa Guay-Woodford; Marschall Runge; Robert Clark; Don McClain; Harry Selker; Curtis Lowery; Steven Dubinett; Lars Berglund; Dan Cooper; Gary Firestein; S Clay Johnston; Julian Solway; James Heubi; Ronald Sokol; David Nelson; Larry Tobacman; Gary Rosenthal; Lauren Aaronson; Richard Barohn; Philip Kern; John Sullivan; Thomas Shanley; Bruce Blazar; Richard Larson; Garret FitzGerald; Steven Reis; Thomas Pearson; Thomas Buchanan; David McPherson; Allan Brasier; Robert Toto; Mary Disis; Marc Drezner; Gordon Bernard; John Clore; Bradley Evanoff; Julianne Imperato-McGinley; Robert Sherwin; Jill Pulley
Journal:  Clin Transl Sci       Date:  2012-03-27       Impact factor: 4.689

Review 9.  CTSA-IP: a solution to identifying and aggregating intellectual property across the NIH Clinical Translational Science Award (CTSA) consortium of biomedical research institutes.

Authors:  Mike Hazard; Scott Steele; Dongwen Wang; Thomas Pearson; Mark Scheideler; Steve Dewhurst
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

Review 10.  Cancer nanomedicines: so many papers and so few drugs!

Authors:  Vincent J Venditto; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.